Loading…

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Fu...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-12, Vol.16 (1), p.126
Main Authors: Tarpgaard, Line Schmidt, Winther, Stine Brændegaard, Pfeiffer, Per
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3
container_end_page
container_issue 1
container_start_page 126
container_title Cancers
container_volume 16
creator Tarpgaard, Line Schmidt
Winther, Stine Brændegaard
Pfeiffer, Per
description Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).
doi_str_mv 10.3390/cancers16010126
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777930</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779132435</galeid><sourcerecordid>A779132435</sourcerecordid><originalsourceid>FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</originalsourceid><addsrcrecordid>eNptkktv1TAQhSNERau2a3YoEhs2acePOAkbVF3RghSpUilr49jj4iqxL3ZSCX49Di19qfbCo_F3znisKYq3BI4Y6-BYK68xJiKAAKHiVbFHoaGVEB1__SjeLQ5Tuoa8GCONaN4Uu6ylQOqa7RU_LiOqeUI_l-fb2QWfSufLXs1Y9c5juQljiKhnNZabf-U-lj2mtHI9qujRlDaGqbxAvXpcKG_C5P7k9Ld5MQ7TQbFj1Zjw8O7cL76ffr7cfKn687Ovm5O-0pyzuSLWMEOZsgpsjd2gSQM4gGg7KgQ1xNCurZW1bUP0AJyKDlrVAoehVYyAYfvFp1vf7TJMaNbXRDXKbXSTir9lUE4-vfHup7wKN5JA0zQdg-zw4c4hhl8LpllOLmkcR-UxLEnSjjBeQ8tFRt8_Q6_DEn3ub6VozTsQ9IG6UiNK523IhfVqKk9yScIoZ3Wmjl6g8jY4OR08WpfzTwTHtwIdQ0oR7X2TBOQ6GPLZYGTFu8d_c8__HwP2F2wSs3k</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912549062</pqid></control><display><type>article</type><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>PubMed Central(OpenAccess)</source><creator>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</creator><creatorcontrib>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</creatorcontrib><description>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16010126</identifier><identifier>PMID: 38201553</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Angiogenesis ; Antimitotic agents ; Antineoplastic agents ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Clinical trials ; Colorectal cancer ; Colorectal carcinoma ; ErbB-2 protein ; FDA approval ; Gene mutations ; Genetic aspects ; Irinotecan ; Kinases ; Metastases ; Metastasis ; Monoclonal antibodies ; Mutation ; Oncology ; Oncology, Experimental ; Oxaliplatin ; Patients ; Quality of life ; Review ; Trifluridine ; Tumors</subject><ispartof>Cancers, 2023-12, Vol.16 (1), p.126</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</cites><orcidid>0000-0002-2925-0586 ; 0000-0001-8505-2544</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2912549062/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2912549062?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38201553$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tarpgaard, Line Schmidt</creatorcontrib><creatorcontrib>Winther, Stine Brændegaard</creatorcontrib><creatorcontrib>Pfeiffer, Per</creatorcontrib><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</description><subject>Angiogenesis</subject><subject>Antimitotic agents</subject><subject>Antineoplastic agents</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>ErbB-2 protein</subject><subject>FDA approval</subject><subject>Gene mutations</subject><subject>Genetic aspects</subject><subject>Irinotecan</subject><subject>Kinases</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Oncology, Experimental</subject><subject>Oxaliplatin</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Review</subject><subject>Trifluridine</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptkktv1TAQhSNERau2a3YoEhs2acePOAkbVF3RghSpUilr49jj4iqxL3ZSCX49Di19qfbCo_F3znisKYq3BI4Y6-BYK68xJiKAAKHiVbFHoaGVEB1__SjeLQ5Tuoa8GCONaN4Uu6ylQOqa7RU_LiOqeUI_l-fb2QWfSufLXs1Y9c5juQljiKhnNZabf-U-lj2mtHI9qujRlDaGqbxAvXpcKG_C5P7k9Ld5MQ7TQbFj1Zjw8O7cL76ffr7cfKn687Ovm5O-0pyzuSLWMEOZsgpsjd2gSQM4gGg7KgQ1xNCurZW1bUP0AJyKDlrVAoehVYyAYfvFp1vf7TJMaNbXRDXKbXSTir9lUE4-vfHup7wKN5JA0zQdg-zw4c4hhl8LpllOLmkcR-UxLEnSjjBeQ8tFRt8_Q6_DEn3ub6VozTsQ9IG6UiNK523IhfVqKk9yScIoZ3Wmjl6g8jY4OR08WpfzTwTHtwIdQ0oR7X2TBOQ6GPLZYGTFu8d_c8__HwP2F2wSs3k</recordid><startdate>20231226</startdate><enddate>20231226</enddate><creator>Tarpgaard, Line Schmidt</creator><creator>Winther, Stine Brændegaard</creator><creator>Pfeiffer, Per</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2925-0586</orcidid><orcidid>https://orcid.org/0000-0001-8505-2544</orcidid></search><sort><creationdate>20231226</creationdate><title>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</title><author>Tarpgaard, Line Schmidt ; Winther, Stine Brændegaard ; Pfeiffer, Per</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Angiogenesis</topic><topic>Antimitotic agents</topic><topic>Antineoplastic agents</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>ErbB-2 protein</topic><topic>FDA approval</topic><topic>Gene mutations</topic><topic>Genetic aspects</topic><topic>Irinotecan</topic><topic>Kinases</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Oncology, Experimental</topic><topic>Oxaliplatin</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Review</topic><topic>Trifluridine</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tarpgaard, Line Schmidt</creatorcontrib><creatorcontrib>Winther, Stine Brændegaard</creatorcontrib><creatorcontrib>Pfeiffer, Per</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest research library</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tarpgaard, Line Schmidt</au><au>Winther, Stine Brændegaard</au><au>Pfeiffer, Per</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-12-26</date><risdate>2023</risdate><volume>16</volume><issue>1</issue><spage>126</spage><pages>126-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Systemic treatment of metastatic colorectal cancer (mCRC) has improved considerably over the past 20 years. First- and second-line combinations of 5FU, oxaliplatin, and irinotecan, with or without anti-angiogenic and/or anti-EGFR antibodies, were approved shortly after the turn of the millennium. Further triumphs were not seen for almost 10 years, until the approval of initially regorafenib and shortly after trifluridine/tipiracil. A growing understanding of tumor biology through molecular profiling has led to further treatment options. Here, we review the most recent clinical data for late-line treatment options in mCRC, focusing on randomized trials if available. We include recommendations for options in unselected patients and therapies that should only be offered in patients with distinct tumor profiles (e.g., BRAF mutations, KRAS G12C mutations, HER2 amplification, deficient MMR, or NTRK gene fusions).</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38201553</pmid><doi>10.3390/cancers16010126</doi><orcidid>https://orcid.org/0000-0002-2925-0586</orcidid><orcidid>https://orcid.org/0000-0001-8505-2544</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2072-6694
ispartof Cancers, 2023-12, Vol.16 (1), p.126
issn 2072-6694
2072-6694
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777930
source Publicly Available Content Database (Proquest) (PQ_SDU_P3); PubMed Central(OpenAccess)
subjects Angiogenesis
Antimitotic agents
Antineoplastic agents
Cancer
Cancer therapies
Care and treatment
Chemotherapy
Clinical trials
Colorectal cancer
Colorectal carcinoma
ErbB-2 protein
FDA approval
Gene mutations
Genetic aspects
Irinotecan
Kinases
Metastases
Metastasis
Monoclonal antibodies
Mutation
Oncology
Oncology, Experimental
Oxaliplatin
Patients
Quality of life
Review
Trifluridine
Tumors
title Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T14%3A00%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20Options%20in%20Late-Line%20Colorectal%20Cancer:%20Lessons%20Learned%20from%20Recent%20Randomized%20Studies&rft.jtitle=Cancers&rft.au=Tarpgaard,%20Line%20Schmidt&rft.date=2023-12-26&rft.volume=16&rft.issue=1&rft.spage=126&rft.pages=126-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16010126&rft_dat=%3Cgale_pubme%3EA779132435%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c443t-1fd3d23afa0f5e9bc170eb06892662d1d2985aff871cb0426908a8040b8a310d3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2912549062&rft_id=info:pmid/38201553&rft_galeid=A779132435&rfr_iscdi=true